Extramedullary Plasmacytoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2015-01-13
Clinical Trial Update: CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma [Phase 3]
A Phase 3 clinical trial is evaluating a CDD-based regimen with Bortezomib versus CDD alone in relapsed or refractory multiple myeloma with …